Consequently, thorough investigation of mutations affecting Sp1 and other transcription factor binding sites in the COL7A1 promoter region is warranted in RDEB patients across the spectrum of severity, particularly when only one pathogenic recessive mutation was identified. The gene discussed is SP1; the disease is recessive dystrophic epidermolysis bullosa.